SAN DIEGO, May 26, 2025 — A recent study featured in the Journal of Molecular Diagnostics highlights the successful clinical validation of SeekInCare®, a new, non-invasive blood test that uses multi-omics for the early detection of various cancers. Developed by SeekIn Inc., SeekInCare uses advanced genomic, epigenetic, and proteomic analyses to detect cancer early, offering the potential for better outcomes through earlier treatment.
Key Findings
- Broad Cancer Detection: SeekInCare uses shallow whole-genome sequencing of cell-free DNA (cfDNA) and measures seven protein tumor markers from 8ml of blood drawn from the arm. The test analyzes several key characteristics of cancer, including copy number aberration, fragment size, end motif, and oncogenic virus, combined with artificial intelligence algorithms to distinguish between individuals with and without cancer and predict the likely origin of the cancer.
- Strong Clinical Validation: In a study looking back at the data of 617 cancer patients (with 27 different types of cancer) and 580 individuals without cancer, SeekInCare showed a sensitivity of 60.0% with a specificity of 98.3%, and an area under the curve (AUC) of 0.899. Sensitivity increased with the stage of cancer: 37.7% (stage I), 50.4% (stage II), 66.7% (stage III), and 78.1% (stage IV).
- Real-World Evidence: The test was further validated in an ongoing study of 1,203 individuals, achieving 70.0% sensitivity at 95.2% specificity over a median follow-up of 753 days.
- Performance Comparison: SeekInCare’s performance is comparable to other multi-cancer early detection (MCED) tests currently being developed, suggesting its potential as a valuable tool for widespread cancer screening, especially in high-risk groups.
Addressing Cancer Screening Needs
Despite improvements in cancer treatments, many cancers are still found at advanced stages, where treatment is less effective. Current screening methods are limited to specific cancers and often involve invasive procedures that can discourage people from participating. SeekInCare’s blood-based, multi-omics approach aims to solve these problems by providing non-invasive, broad cancer detection from a single blood sample.
“Our results show that combining multiple molecular indicators from blood can greatly improve the sensitivity and specificity of early cancer detection,” said Dr. Mao Mao, lead author and Founder & CEO of SeekIn Inc. “SeekInCare’s strong performance in both retrospective and prospective studies supports its potential clinical use as a screening tool, particularly for populations at high risk.” The study involved collaboration with leading hospitals in China. The publication can be found at .
About SeekInCare®
SeekInCare® aims to detect cancer when it is still curable. It has been developed as a broad cancer detection test that examines various blood cell-free cancer markers using a multi-omics approach that includes genomic and epigenetic changes along with clinically proven protein biomarkers. Using its proprietary AI- and big data-driven CRS algorithm, SeekInCare is highly effective in detecting many types of cancer with high specificity. SeekInCare is intended for use in individuals with increased cancer risks such as smoking, chronic hepatitis, aging, etc., alongside standard single-cancer screening tests. SeekInCare received CE-IVD Mark in November 2021.
About SeekIn
SeekIn Inc., founded in early 2018 in Shenzhen, China, focuses on early pan-cancer detection through blood tests using next-generation sequencing and artificial intelligence. SeekIn is dedicated to providing advanced and affordable solutions for early cancer detection, monitoring for recurrence after surgery, and evaluating treatment response. SeekIn has also developed new molecular tests for leukemia patients, and its cancer early detection technology has been successfully used in dogs. With its unique technical advances, SeekIn has initiated several research and clinical studies in partnership with top hospitals in China. SeekIn believes that by setting a new standard for early cancer detection, the clinical outcomes for patients with mid- to late-stage cancer can be improved, and the cancer mortality rate can be reduced by 15%. For more information about SeekIn’s innovative technologies and products, visit .
SOURCE SeekIn Inc
“`